Dietz B, Klose H J, Gürtler L, Eberle J, Deinhardt F, Köhler-Vajta K, Peller P
Thromb Haemost. 1986 Aug 20;56(1):50-2.
The retrovirus LAV/HTLV III, highly likely to be responsible for the acquired immunodeficiency syndrome (AIDS) in some recipients of blood products, can be inactivated by chemical and/or heat treatment, so the use of virus-inactivated factor VIII and factor IX preparations for treating hemophilia A and B has become important. We examined hemophilic children and found that those children treated since 1979 with virus-inactivated preparations did not develop antibodies against LAV/HTLV III. In contrast, 77% of patients treated with conventional factor VIII or factor IX preparations had antibodies against this virus.
逆转录病毒LAV/HTLV III极有可能是导致一些血液制品接受者患获得性免疫缺陷综合征（艾滋病）的病因，它可通过化学和/或热处理使其失活，因此使用病毒灭活的凝血因子VIII和凝血因子IX制剂来治疗甲型和乙型血友病变得很重要。我们对血友病患儿进行了检查，发现自1979年以来接受病毒灭活制剂治疗的那些患儿并未产生针对LAV/HTLV III的抗体。相比之下，接受传统凝血因子VIII或凝血因子IX制剂治疗的患者中有77%产生了针对这种病毒的抗体。
